Psoriasis: from pathogenesis to novel therapeutic approaches (Q37789387)

23 August 2017

title

Psoriasis: from pathogenesis to novel therapeutic approaches (English)

1 reference

23 August 2017

0 references

5

Antonio Costanzo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846119

14 July 2024

author name string

Giovanni Monteleone

1

1 reference

23 August 2017

Francesco Pallone

2

1 reference

23 August 2017

Sergio Chimenti

4

1 reference

23 August 2017

Thomas T. MacDonald

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846119

14 July 2024

language of work or name

English

0 references

publication date

1 January 2011

1 reference

full work available at URL

23 August 2017

https://portlandpress.com/clinsci/article-pdf/120/1/1/441334/cs1200001.pdf

1 reference

14 July 2024

1 reference

23 August 2017

volume

120

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

1-11

1 reference

A classification of psoriasis vulgaris according to phenotype

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Psoriasis in Australian twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Family studies in psoriasis. I. Complex segregation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

An update on the genetics of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

The PSORS1 locus gene CCHCR1 affects keratinocyte proliferation in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Polymorphisms of the IL12B and IL23R genes are associated with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Resident and "inflammatory" dendritic cells in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Impaired Langerhans cell migration in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Immunopathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Antimicrobial peptides and self-DNA in autoimmune skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

The IL-23/Th17 axis in the immunopathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Psoriasis--as an autoimmune disease caused by molecular mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Peptidoglycan and peptidoglycan-specific Th1 cells in psoriatic skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

A polymer-type water-soluble peptidoglycan exhibited both Toll-like receptor 2- and NOD2-agonistic activities, resulting in synergistic activation of human monocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

How are T(H)1 and T(H)2 effector cells made?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Cytokines and T-cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Development, cytokine profile and function of human interleukin 17-producing helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Increased expression of interleukin 17 in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Transcriptional regulation of Th17 cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Current and future management of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Long-term efficacy of biologics in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

A new era in the management of psoriasis? The biologics: facts and controversies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Certolizumab pegol for the management of Crohn's disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Certolizumab pegol in active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100163

Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling

21 January 2018

1 reference

31 May 2024

https://opencitations.net/index/api/v1/citations/10.1172/JCI40202

Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction

1

1 reference

The genetics of psoriasis: a complex disorder of the skin and immune system

14 July 2024

6

1 reference

Skin immune sentinels in health and disease

14 July 2024

19

1 reference

Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells

14 July 2024

20

1 reference

Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8.

14 July 2024

24

1 reference

Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C

14 July 2024

26

1 reference

Natural killer and natural killer-T cells in psoriasis

14 July 2024

34

1 reference

Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes

14 July 2024

36

1 reference

Dynamic frequency of CD4+CD25+Foxp3+ Treg cells in psoriasis vulgaris

14 July 2024

43

1 reference

Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study

14 July 2024

44

1 reference

Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells

14 July 2024

45

1 reference

Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris

14 July 2024

47

1 reference

Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity

14 July 2024

53

1 reference

Coeliac disease associated with psoriasis

14 July 2024

57

1 reference

Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes

14 July 2024

68

1 reference

Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus

14 July 2024

72

1 reference

Increased interleukin-17 production in patients with systemic sclerosis

14 July 2024

73

1 reference

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

14 July 2024

74

1 reference

Expression of interleukin-12 is increased in psoriatic skin

14 July 2024

80

1 reference

IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation

14 July 2024

85

1 reference

IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis

14 July 2024

88

1 reference

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

14 July 2024

96

1 reference

Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature

14 July 2024

100

1 reference

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

14 July 2024

113

1 reference

14 July 2024

Identifiers

DOI

10.1042/CS20100163

1 reference

23 August 2017

1 reference